Seminars in Hematology

Papers
(The TQCC of Seminars in Hematology is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Special issue on chronic lymphocytic leukemia: Prognostication and therapeutic options introductory editorial158
CAR T-cell therapy comes of age: Introductory editorial for the special issue67
Clinical applications of circulating tumor DNA in Hodgkin lymphoma45
Extramedullary myeloma in the era of CAR T-cell and bispecific antibody therapies37
Insights from the 12th International Workshop on Waldenstrom's Macroglobulinemia37
Evolving insights into mitochondrial presence in RBC in sickle cell disease: Red blood cell and reticulocyte pathophysiology, therapeutic strategies, and future directions35
Updates on current and future research in acute myeloid leukemia32
How to set up a clinical research center in Brazil, as an example of a middle-income country28
The winding road: Infectious disease considerations for CAR-T and other novel adoptive cellular therapies in the era of COVID-1923
Lessons learned from the Eµ-TCL1 mouse model of CLL22
Epidemiology and etiology of diffuse large B-cell lymphoma22
The role of viruses in HIV-associated lymphomas21
Immune-driven clonal cell selection at the intersection among cancer, infections, autoimmunity and senescence21
The future of lymphoma diagnosis, prognosis, and treatment monitoring in countries with limited access to pathology services19
More disease-modifying therapies for sickle cell disease: Are small molecules and drug repurposing the way forward?18
MRD-driven treatment strategies in CLL: Current practice, limitations, and emerging paradigms18
Antibody and immunotherapy in diffuse large B-cell lymphoma18
TET2 mutation as prototypic clonal hematopoiesis lesion18
Accelerating accessibility of CAR-T/NK therapies – Are AlloCARs and rapid manufacturing platforms the road ahead in improving access in multiple myeloma?17
Intestinal microbiome and myelodysplastic syndromes: Current state of knowledge and perspectives for future17
The molecular map of CLL and Richter's syndrome15
Developing MRD as an early endpoint for accelerated approval in CLL14
Vaccinations in patients with chronic lymphocytic leukemia14
T-cell engaging antibodies for B-cell lymphomas14
Report of Consensus Panel 5 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors14
Roadmap for developing MRD as an early endpoint for drug approval in lymphoma14
At the cusp of a cure in Myeloma: Insights into pathogenesis, modeling and therapeutics13
Clonal hematopoiesis13
Cellular and immunotherapies for myelodysplastic syndromes12
B-cell receptor immunoglobulin stereotypy in chronic lymphocytic leukemia: Key to understanding disease biology and stratifying patients12
outside front cover, PMS 8883 metallic AND 4/C12
Role of MRD testing in acute myeloid leukemias. What is the status and how to get there?12
Challenges and opportunities of CAR T-cell therapies for CLL11
Advancements in bispecific antibodies for multiple myeloma: What's new and what lies ahead11
outside front cover, PMS 8883 metallic AND 4/C11
The biology of classical Hodgkin lymphoma10
Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia10
Management of Myelodysplastic Syndrome in Pregnant Patients: Treatment Approaches and Considerations10
Access to essential therapy for sickle cell disease in Africa: Experience from a national program in Ghana9
Treatment of myeloproliferative neoplasms: Exploring new horizons of who and when to cytoreduce in patients with polycythemia vera and essential thrombocytosis9
Engineering the Next Generation of Antibody Therapeutics in Hematology9
Mobilizing CARs: Benefits, drawbacks, and directions for outpatient CAR T-cell therapy9
outside front cover, PMS 8883 metallic AND 4/C9
The pediatric approach to Hodgkin lymphoma8
Report of Consensus Panel 2 from the 12th International Workshop on the management of Bing-Neel syndrome in patients with Waldenstrom’s Macroglobulinemia8
Understanding MDS stem cells: Advances and limitations8
A tower of babel of acronyms? The shadowlands of MGUS/MBL/CHIP/TCUS8
Harnessing single-domain antibodies for CAR-T and bispecific antibody development8
Clinical applications of circulating tumor DNA in central nervous system lymphoma8
Menin inhibition for the treatment of acute leukemia8
Blood-based MRD testing in multiple myeloma: Update on mass spectrometry methods for detecting the monoclonal immunoglobulin8
Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials8
Infectious complications of chimeric antigen receptor (CAR) T-cell therapies7
MRD as an early endpoint in myeloma and other hematologic malignancies: Implication for ongoing and future study designs7
The emergence of a new paradigm with signal 1 and signal 2 T-cell engagers in hematology7
outside front cover, PMS 8883 metallic AND 4/C7
DLBCL arising from indolent lymphomas: How are they different?7
Modernizing multiple myeloma clinical trial eligibility to improve equity and inclusivity by hematological parameters7
The crossroads of cancer therapies and clonal hematopoiesis7
0.11897206306458